Abnormal glucose tolerance is a frequent late complication of cystic fibrosis (CF), but the prevalence of CF-related diabetes mellitus (CFRD) in children less than 10 y old is less than 2%. The youngest child with CFR...Abnormal glucose tolerance is a frequent late complication of cystic fibrosis (CF), but the prevalence of CF-related diabetes mellitus (CFRD) in children less than 10 y old is less than 2%. The youngest child with CFRD reported to date was 6 mo of age. Insulinopenia is the primary cause of abnormal glucose toleranceCFRD, but it is unknown whether it may begin in the neonatal period. We describe a case of a neonate with CF who presented with hyperglycaemia in the diabetic range and marked insulinopenia. Insulinopenia and impaired glucose tolerance were permanent findings at 6 and 15 mo of age. Conclusion: This case suggests that abnormal glucose tolerancediabetes may occur much earlier in the course of CF, even during neonatal age. Careful follow-up and further studies in CF infants could reveal that the real incidence of glucose intolerance and diabetes in this age group has been underestimated.展开更多
Aim:To assess the effect of cyclosporine A(CyA)on the level of vascular endothelial growth factor(VEGF)in the plasma and urine of nephrotic syndrome children.Methods:The study material consisted of 15 children(F 6,M 9...Aim:To assess the effect of cyclosporine A(CyA)on the level of vascular endothelial growth factor(VEGF)in the plasma and urine of nephrotic syndrome children.Methods:The study material consisted of 15 children(F 6,M 9;group I)who were subjected to the following examinations:A)at the time of proteinuria relapse,before treatment with CyA,B)after 3 mo,C)after 6 mo,and D)after 12 mo of CyA administration with prednisone and convertase inhibitor.The control group(II)-contained 20 healthy children.The immunoenzymatic ELISA method(R&D Quantikine)was used to determine plasma and urinary VEGF levels,while the immunofluorescence method was applied to assess CyA concentration in the plasma.The statistical program Statistica 6.0 was used for statistical analysis of the results.Results:In the present study,plasma VEGF level in examination A was higher than in the control group(P < 0.01).After proteinuria regression(B),it did not differ from the level observed in healthy children(P > 0.05).After 6 and 12 mo of CyA administration,VEGF concentration increased and was higher than in the control group(P < 0.05).In all the examinations,urinary excretion of VEGF was higher than in the control group,increasing proportionally with the duration of treatment and plasma CyA level.A positive correlation was observed between plasma and urinary VEGF levels and between VEGF and CyA concentrations in the plasma.Conclusion:Long-term CyA treatment of nephrotic syndrome children leads to an increase in plasma and urinary VEGF.展开更多
We studied the association between genetic polymorphisms of the renin-angiotensin system and the risk for circulatory failure (CF) during the first three postnatal days in 104 very low-birthweight preterm infants. Con...We studied the association between genetic polymorphisms of the renin-angiotensin system and the risk for circulatory failure (CF) during the first three postnatal days in 104 very low-birthweight preterm infants. Conclusion: Infants with angiotensin-converting enzyme DD genotype were protected against CF (adjusted OR 0.41, 95%CI 0.19-0.89).展开更多
文摘Abnormal glucose tolerance is a frequent late complication of cystic fibrosis (CF), but the prevalence of CF-related diabetes mellitus (CFRD) in children less than 10 y old is less than 2%. The youngest child with CFRD reported to date was 6 mo of age. Insulinopenia is the primary cause of abnormal glucose toleranceCFRD, but it is unknown whether it may begin in the neonatal period. We describe a case of a neonate with CF who presented with hyperglycaemia in the diabetic range and marked insulinopenia. Insulinopenia and impaired glucose tolerance were permanent findings at 6 and 15 mo of age. Conclusion: This case suggests that abnormal glucose tolerancediabetes may occur much earlier in the course of CF, even during neonatal age. Careful follow-up and further studies in CF infants could reveal that the real incidence of glucose intolerance and diabetes in this age group has been underestimated.
文摘Aim:To assess the effect of cyclosporine A(CyA)on the level of vascular endothelial growth factor(VEGF)in the plasma and urine of nephrotic syndrome children.Methods:The study material consisted of 15 children(F 6,M 9;group I)who were subjected to the following examinations:A)at the time of proteinuria relapse,before treatment with CyA,B)after 3 mo,C)after 6 mo,and D)after 12 mo of CyA administration with prednisone and convertase inhibitor.The control group(II)-contained 20 healthy children.The immunoenzymatic ELISA method(R&D Quantikine)was used to determine plasma and urinary VEGF levels,while the immunofluorescence method was applied to assess CyA concentration in the plasma.The statistical program Statistica 6.0 was used for statistical analysis of the results.Results:In the present study,plasma VEGF level in examination A was higher than in the control group(P < 0.01).After proteinuria regression(B),it did not differ from the level observed in healthy children(P > 0.05).After 6 and 12 mo of CyA administration,VEGF concentration increased and was higher than in the control group(P < 0.05).In all the examinations,urinary excretion of VEGF was higher than in the control group,increasing proportionally with the duration of treatment and plasma CyA level.A positive correlation was observed between plasma and urinary VEGF levels and between VEGF and CyA concentrations in the plasma.Conclusion:Long-term CyA treatment of nephrotic syndrome children leads to an increase in plasma and urinary VEGF.
文摘We studied the association between genetic polymorphisms of the renin-angiotensin system and the risk for circulatory failure (CF) during the first three postnatal days in 104 very low-birthweight preterm infants. Conclusion: Infants with angiotensin-converting enzyme DD genotype were protected against CF (adjusted OR 0.41, 95%CI 0.19-0.89).
